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System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam 
Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective 
Kristen R. Nichols, Chad A. Knoderer, Elaine G. Cox, Michael B. Kays 
Abstract 
Background 
Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, 
but data in children are limited. 
Objective 
The goal of this study was to determine the feasibility of using an extended-infusion PT dosing 
strategy as the standard of care in a children's hospital. 
Methods 
This was a prospective observational study of patients aged >30 days who received PT after 
admission to a freestanding, tertiary care children's hospital. After institution of an extended-
infusion PT dosing protocol as the standard dosing option, patients receiving PT were 
prospectively assessed for presence of and reasons for changes in dosing regimen. 
Results 
A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and 
median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on 
piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% 
(n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, 
with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed 
traditional infusion PT. The most commonly encountered reason for not using extended infusions 
was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. 
Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few 
observed dosing errors were likely attributable to the overall ordering process at our institution, 
which requires ordering as the milligram per kilogram dose as total PT rather than based on 
piperacillin component as is commonly documented in pediatric dosing references. 
Conclusions 
Results of this study suggest that extended-infusion PT dosing was feasible in this specific 
children's hospital. Ninety-two percent of patients received our institution's preferred dosing 
regimen; a small percentage of patients still needed to receive traditional infusion times. 
Introduction 
Increasing prevalence of antimicrobial resistance is a growing issue encountered on a daily basis 
in hospitals caring for children.
1, 2, 3, 4, 5 and 6
 Few alternative antibacterial agents are available to 
treat infections caused by multidrug resistant bacteria, primarily due to limited available 
pediatric tolerability and efficacy data and, ultimately, limited published experience with using 
such agents in pediatric patients. With developmental pharmacologic changes observed along the 
continuum of “pediatrics,” simply extrapolating adult dosages to a pediatric patient is not always 
the safest or most effective approach.
7
 Although detrimental effects on development have not 
been documented, there are few published data to establish optimal use, dose, and duration for 
alternatives to β-lactam antibacterial agents such as fluoroquinolones, aminoglycosides, 
tetracycline derivatives, and colistin. However, these medications may represent the entire 
antibacterial arsenal for the treatment of infections caused by resistant gram-negative bacteria in 
children, thereby requiring careful risk/benefit assessments. As with adult studies, pediatric 
studies have reported negative clinical outcomes associated with infections due to resistant 
bacteria, including increased length of stay and mortality.
2 and 8
 
From a pediatric care perspective, it is critical to optimize the dosing of the currently available 
antibacterial agents based on drug-specific pharmacokinetic and pharmacodynamic parameters, 
thus increasing the probability that positive patient outcomes are maximized while minimizing 
the selective pressure for emergence of antibiotic resistance.
9 and 10
 In general, β-lactam 
antibiotics and antibiotic combinations, such as piperacillin-tazobactam (PT), exhibit time-
dependent bactericidal activity and, with the exception of carbapenems, minimal postantibiotic 
effects.
9
 As a result, their pharmacodynamics are optimized by achieving a requisite length of 
time for which the free antibiotic concentrations remain above the MIC (fT > MIC) for the 
infecting organism. There is no apparent difference between adults and children with respect to 
these pharmacodynamic properties. Thus, any potential or proven benefits of optimizing 
pharmacodynamic exposures should apply to children as well as to adults. 
Optimization of the PT bactericidal exposures can be achieved by increasing the dose while 
keeping the dosing interval the same, administering the same dose at more frequent intervals, 
administering the dose as a continuous infusion, or extending the duration of intermittent 
infusions.
11
 Although there are certain pharmacokinetic differences observed between children 
and adults, the pharmacokinetic profiles of piperacillin and tazobactam, specifically t½ values, 
reach adult values by 2 years of age.
7, 12 and 13
 Doubling the dose of PT increases the fT > MIC by 
only ∼1 t½ of the medication. 
14
 Administering the medication at more frequent intervals would 
require 4-hour dosing intervals compared with 6-hour intervals, which may create a significant 
burden on nursing staff depending on the institution. 
A potential solution is to use continuous or extended-infusion dosing strategies in children. 
Extended-infusion PT (EIPT) has been well described in adult patients, and many adult studies 
have evaluated the attainment of the target % fT > MIC by using Monte Carlo simulation. 
11, 15, 16, 
17, 18, 19, 20, 21, 22, 23, 24 and 25
 Lorente et al 
26
 reported superior clinical cure in ventilator-associated 
pneumonia with continuous versus intermittent PT infusions. Although not definitive with 
respect to extended-infusion dosing, the findings provide support for improved clinical outcomes 
with optimizing dosing strategies of our existing antibacterial agents to maximize fT > MIC. A 
common concern when considering continuous or extended-infusion regimens in children is that 
compatibility issues could arise due to the child's limited number of intravenous (IV) access 
sites, although this is less problematic with extended-infusion regimens compared with 
continuous infusion regimens. 
After conducting a PubMed search using combinations of the terms piperacillin/tazobactam, 
beta-lactam, pharmacodynamics, pharmacokinetics, prolonged infusion, and extended infusion, 
it was determined that description of EIPT in a pediatric population is limited to 1 study which 
explored the probability of pharmacodynamic target attainment using Monte Carlo simulations 
and no direct patient intervention. 
27
 By simulating an extended or continuous infusion of β-
lactam antibacterial agents, the authors reported an increased probability of target attainment for 
Pseudomonas aeruginosa isolates with elevated MICs. Although this study is useful for 
estimating effects of prolonged infusion, an ability to administer medications as prolonged or 
continuous infusions in actual patients was not addressed. Having implemented an EIPT dosing 
protocol in our institution, the objective of the current study was to describe implementation of 
an EIPT dosing strategy as the standard of care in a children's hospital. 
Methods 
Study Population and Setting 
This was a descriptive study performed after the implementation of EIPT as the standard of care 
in a freestanding, tertiary care children's hospital. At our institution, PT is a common 
combination antibacterial agent for suspected or confirmed gram-negative bacterial infections. 
Traditionally, it has been dosed at 75 mg/kg/dose (based on piperacillin component) every 6 to 8 
hours via a 30-minute infusion. In April 2011, our health system's Pharmacy and Therapeutics 
Committee, with the support of the Pediatric Antimicrobial Stewardship Program (PAS), 
approved a system-wide change to 4-hour infusions of PT. Based on our institutional 
susceptibility data, it was estimated that the target fT > MIC would be achieved in 15% to 30% 
more isolates of P aeruginosa with EIPT. This was a system-wide change in dosing strategy for 
both pediatric and adult patients in each of the system hospitals, with PAS support. After 
hospital-wide education to pharmacists, physicians, and nurses provided by PAS members and 
the nursing education team, our hospital changed its traditional practice to dosing PT at 100 
mg/kg/dose (based on piperacillin component) every 8 hours via 4-hour infusion. This regimen 
became the standard PT dose and administration method for all patients in the hospital with the 
exception of neonates or patients encountered in the neonatal intensive care unit, operating areas, 
outpatient infusion clinics, or emergency department. Although published pediatric 
pharmacodynamic simulations used a 3-hour infusion time, our hospital is part of a larger health 
care system consisting of both adult and adult/pediatric mixed hospitals, and a 4-hour infusion 
time was chosen for system standardization as well as smart pump programming. 
27
 
Prescribers within our institution are required to order IV antibacterial agents via a preprinted 
order form. Implementation of the new dosing strategy included changing the dosing on the 
required preprinted form to the extended-infusion regimen and removing the traditional 30-
minute infusion. Prescribers were allowed to order PT via a 30-minute infusion if they thought 
that dosing was medically necessary, but prescribers had to write the entire medication order, 
including dose, on a blank line on the order form. Both the 4-hour and 30-minute infusions were 
administered by using an Alaris Pump (CareFusion Corporation, San Diego, California). 
Patients were included if they received at least 1 dose of IV PT within our institution from April 
5, 2011, to July 5, 2011, which was a period after EIPT implementation. Patients were identified 
daily by using the pharmacy computer system and by reviewing inpatient antibacterial orders. 
Exclusion criteria were admission to the neonatal intensive care unit, age <30 days, and PT 
administration in the operating areas, outpatient infusion clinics, or emergency department. 
These exclusions were the same as are listed in the hospital's EIPT dosing protocol. The 
institutional review board at Indiana University–Purdue University at Indianapolis approved the 
study with waiver of consent. 
Data were collected prospectively from the patient's medical record as a quality assurance project 
relating to the relationship of PAS and the Quality Council at our institution. Subsequently, 
exempt institutional review board approval was granted on the decision to share our experience. 
Patient demographic characteristics were collected in addition to PT dosing information (dose, 
frequency, infusion time, and duration of therapy), concomitantly ordered medications, number 
of available IV lumens, and indication for PT. Medications and IV access points were 
documented once at the time of data collection, although these parameters may have been 
frequently changing. Therapy was defined as targeted if a specific infection was targeted (cystic 
fibrosis exacerbation, positive culture, perforated appendicitis, and hospital-acquired pneumonia) 
or empiric if PT was administered for febrile neutropenia or in the process of ruling out an 
infection. Reasons for not using the 4-hour infusion time were obtained as documented in the 
medical record; pharmacists or physicians were queried for this information if it was not found in 
the medical record. At the end of the study period, the institutional IV placement team was 
questioned regarding an observed change in peripheral IV placement. The primary outcome in 
this study was the feasibility of EIPT, determined by the percentage of PT courses that were 
changed to the traditional 30-minute infusion. A low percentage (<20%) of use of traditional 
infusions would confirm feasibility of this dosing strategy. 
Statistical Analysis 
Descriptive statistics were used for patient demographic characteristics, the percentage of PT 
courses administered via extended infusion, and the percentage of dosing errors. Statistical 
analysis was conducted by using Microsoft Excel 2007 (Microsoft Corporation, Redmond, 
Washington). 
Results 
A total of 332 patients met study inclusion. Median patient age was 5 years (interquartile range, 
1.9–12 years), and median weight was 19.9 kg (interquartile range, 11.7–37.6 kg). Age 
distribution is described in Table I. The pediatric critical care, hematology/oncology, general 
surgery, and pulmonary services were responsible for prescribing 65.1% (n = 216) of PT courses. 
Approximately 45% of patients received PT as empiric therapy while awaiting culture results 
(“rule outs”) or for febrile neutropenia (Table II). The mean duration of PT therapy was 4.5 
(4.2) days, with 51.2% (n = 170) of courses lasting <72 hours. Sixty-four (19.3%) courses of PT 
continued for >7 days. Courses of duration >72 hours but <7 days likely represent antibiotic de-
escalation based on culture and susceptibility results or diagnostic indecision. A total of 174 
(52.4%) patients had only 1 IV access point at time of PT initiation, and 107 (32.3%) had only 2 
IV access points; 149 (44.9%) patients had only peripheral access. 
 
 
Table I.
        Demographic characteristics (N = 332).
Male 50.60%
Median age (IQR), y 5 (1.9-12)
Age,  no. (%)
 <1 y 55 (16.6)
 1-5y 118 (35.5)
 6-11 y 67 (20.2)
 12-17 y 58 (17.5)
≥18 y 34 (10.2)
Prescribing pediatric medical service,  no. (%)
 Burn 1 (0.3)
 Cardiology/cardiovascular surgery 23 (6.9)
 Critical care 67 (20.2)
 Developmental 17 (5.1)
 Gastroenterology 10 (3.0)
 General surgery 39 (11.7)
 Genitourinary 11 (3.3)
 Hematology/oncology 75 (22.6)
 Hospitalist 6 (1.8)
 Infectious diseases 3 (0.9)
 Nephrology 4 (1.2)
 Neurosurgery 4 (1.2)
 Orthopedics 4 (1.2)
 Plastic surgery 9 (2.7)
 Pulmonary 35 (10.5)
 Transplant 13 (3.9)
 Trauma 3 (0.9)
 Stem cell transplant 8 (2.4)
 Twenty-eight (8.5%) of the 332 study patients who qualified for EIPT according to hospital 
protocol were given traditional dosing and infusion times. Nineteen of those patients (5.7% of all 
patients) were originally prescribed EIPT and were subsequently changed to traditional dosing 
during therapy. Documented reasons for using a 30-minute infusion are shown in Table III. 
 
Dosing errors occurred in a low percentage of patients who received PT (n = 6 [1.8%]). Five 
patients were given doses lower than intended for EIPT. Two of these patients were prescribed 
doses more similar to the traditional dosing (75 mg/kg every 6 hours). Three errors occurred 
when patients received 90 mg/kg instead of 100 mg/kg as an extended infusion. In 1 case, a 
prescriber ordered standard traditional dosing regimen, and that dose was lower than typically 
used at our institution (65 mg/kg every 6 hours). Four nondosing medication errors were 
reported. Precipitation occurred in 1 case when vancomycin was administered shortly after PT, 
although the catheter was flushed with 20 mL of D5 ½NS with 10 mEq of KCl per liter (the 
patient's maintenance fluid) after PT administration and before vancomycin administration. 
Doses were infused over an incorrect time period twice; in 1 case, a 4-hour infusion was given 
over 30 minutes and in the other case, a 30-minute infusion was given over 4 hours. The final 
error occurred when an EIPT milligram dose was changed, but the order was entered to be 
administered over and was given over 30 minutes rather than 4 hours. In cases of incorrect 
infusion time, no patient experienced an adverse effect. 
Table II.
        Indications for piperacillin/tazobactam prescription (N = 332).
Indication No. (%) of Patients
Abdominal infection 32 (9.6)
Community-acquired pneumonia 20 (6.0)
Cystic fibrosis 18 (5.4)
Febrile neutropenia 58 (17.5)
Hospital-/health care-/ventilator-associated pneumonia 20 (6.0)
Directed therapy (blood or urine culture) 25 (7.5)
Rule-out infection 92 (27.7)
Tracheitis 13 (3.9)
Urinary tract infection (empiric) 7 (2.1)
Other 47 (14.2)
Table III.
Documented reasons for 30-minute piperacillin-tazobactam infusion (n = 28).
Reason No. (%) of Patients
Incompatibility with vancomycin coadministration 17 (60.7%)
Incompatibility with other IV medications 5 (17.9%)
Concern for limited IV access 2 (7.1%)
Prescriber confusion 2 (7.1%)
Dosing adjustment in acute kidney injury 1 (3.6%)
Organ procurement protocol 1 (3.6%)
Discussion 
One advantage of the extended-infusion dosing strategy is the improvement in the probability of 
target attainment for microorganisms with higher MICs.
27
 Critics may argue that the number of 
organisms with elevated MICs is lower in the pediatric population compared with the adult 
population. Although it may be true that children are less likely to be infected with resistant 
organisms compared with adults, higher MICs are certainly observed for organisms infecting 
children.
3, 6 and 27
 Furthermore, optimizing dosing on the basis of pharmacodynamic parameters 
may delay development of further resistance in this population, suggesting that such strategies 
may be particularly effective when introduced before observation of elevated MICs.
10
 
Another potential advantage is the economic benefit of the extended infusion strategy. In adults, 
lower daily doses administered by using extended infusion achieve comparable 
pharmacodynamic exposures to higher daily dosing regimens administered by intermittent 
infusion.
16
 The omission of 1 daily dose can lead to cost savings although this is of uncertain 
benefit in children, in whom the medication cost per dose is lower than in adults. However, 
preparation and administration of 3 doses daily versus 4 doses (the resulting difference with 
EIPT compared with traditional dosing in our institution), are associated with a decrease in 
pharmacy preparation and nurse administration time costs. These costs are more difficult to 
quantify than medication acquisition costs, but they are equally important. In addition, reducing 
the daily number of IV line accesses may be a beneficial infection control consideration. By 
limiting possible complications such as catheter-associated bloodstream infections and 
associated effects on length of stay, by potentially decreasing infections with multidrug-resistant 
organisms, and by optimizing outcomes, cost benefits may be substantial with this dosing 
strategy. 
Extended-infusion PT regimens were successfully implemented as the standard of care at our 
freestanding children's hospital. Ninety-two percent of patients received extended infusion 
dosing of PT. Only 8.4% of PT courses that could have been dosed by extended infusion were 
dosed using the traditional 30-minute infusion. Of the courses administered over 30 minutes, 
86% (24 of 28) were due to incompatibility issues or practitioner concerns. 
A preprinted order form is required for ordering IV antibiotics at our institution. When the 
dosing on the order form was changed to reflect EIPT (every 8-hour dosing administered over 4 
hours), there were concerns raised that prescribers desiring an every 6-hour dosing regimen 
would be more likely to choose a dose that was inappropriate. Since implementation of EIPT, the 
incidence of dosing errors has been low. However, there are no “baseline” data with which to 
compare this, and errors are voluntarily reported. The few observed dosing errors were likely 
attributable to the overall ordering process at our institution, which requires ordering as the 
milligram per kilogram dose as total PT rather than based on piperacillin component as is 
commonly documented in pediatric dosing references. We suspect that the dosing errors were 
more likely due to the overall ordering process than to a change in dosing protocol. 
A fewer number of IV access points in combination with a sometimes large number of necessary 
IV medications, with or without compatibility information, may be more of a challenge in a 
small child compared with a larger adult. Limited IV access resulting in compatibility concerns 
was the indication for reversion to the traditional dosing in 86% of occurrences, but the overall 
incidence of reversion to traditional dosing from EIPT due to this reason was 7%. 
Another barrier suggested before EIPT implementation was that, to comply with the dosing 
strategy, there would be an increased placement of IV catheters in the pediatric patients. Indeed, 
addition of more IV access sites to accommodate this dosing strategy is a concern given the 
increased risk of infection of new IV access sites, which is why this practice was discouraged at 
our institution. Although prescribers were instructed to change dosing instead of adding 
additional IV access, it is possible that IV access did increase. Unfortunately, this study did not 
include comparing patients receiving extended infusion with patients receiving traditional 
infusion. However, the “IV team” at the institution, which is responsible for obtaining peripheral 
IV access in patients with difficult-to-obtain IV access, observed no increased requests for 
peripheral IV insertion after implementation of EIPT. It was also shown that central access was 
not necessary for use of this dosing regimen, as 45% of patients had only peripheral access at the 
time of antibiotic initiation. 
The largest observed barrier to administration of EIPT was the lack of medication compatibility 
information, especially with vancomycin. Compatibility data for the concentrations of PT and 
vancomycin used at our institution (112.5 mg/mL of PT and 10 mg/mL of vancomycin) are not 
available, and compatibility for other concentrations is reported to be variable.
28
 
There are limitations to the current study. It may be difficult to generalize our findings and 
experience to other hospitals or units providing medical care to children because our institution is 
a tertiary care pediatric hospital with an overall institutional support structure, in both personnel 
and technological resources, for this type of dosing change. Administration issues and 
medication variances may have been present and either escaped identification or documentation 
during the implementation. However, it is unlikely that a large number of unidentified errors or 
problems occurred without drawing the attention of the prescribers or the nursing staff who were 
highly invested in the dosing change. Our study period immediately followed EIPT 
implementation, and it is not evident if our immediate findings will be continued. However, we 
have no evidence to suggest that our success will not be sustainable. 
Conclusions 
Results of this study suggest that extended-infusion PT dosing was feasible in this specific 
children's hospital. A high percentage of patients (92%) received our institution's preferred 
dosing regimen; a small percentage of patients still needed to receive traditional infusion times. 
Additional studies are warranted to determine the impact of this new dosing regimen on clinical 
outcomes and prevalence of bacterial resistance. 
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